Sosei drug fails Phase II, but hope remains

Researchers for Sosei say that a Phase II trial for an experimental therapy for fibromyalgia failed to hit its primary endpoint, but researchers were quick to highlight encouraging signs of the drug's efficacy. AD 337 failed to hit its goal of statistically significant outcomes at four weeks. But researchers noted that a statistically significant response was seen after one week of dosing and added that other encouraging signs were also evident. Overall, it concluded that the drug has some potential.

"Sosei will be evaluating these results to determine its approach to the possible further development of AD 337 in FMS and other potential indications," said Sosei CEO Shinichi Tamura. 

- check out the release for more info

Related Articles:
Forest Labs reports Phase III failure for fibromyalgia drug. Report
Lilly pursues new Cymbalta approval. Report
Pfizer touts blockbuster drug for fibromyalgia. Report
Sosei drops a drug candidate. Report

Suggested Articles

After culling a $2.6 billion biobucks pact last year, Bristol Myers Squibb is making a second and final cut to its pact with I-O biotech Jounce.

With its $400 million Fund XII, Atlas Venture became the latest VC shop to close a major fund since the WHO officially declared COVID-19 a pandemic.

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.